Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA

Recruiting Observational Study
Spinal Muscular Atrophy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
12 and older
Sex
Any
Study type
Observational
Participants needed
45 (estimated)
Sponsor
Columbia University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of this project is to investigate the utility of the SMA EFFORT, an SMA-specific patient-reported outcome measure, to assess perceived physical fatigability that is anchored to intensity and duration of activities. We aim to characterize perceived physical fatigability (PPF) in a diverse cohort of people with SMA (pwSMA) and evaluate the change of PPF before and after nusinersen dosing…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. All types of 5qSMA (homozygous deletion or point mutation of the SMN1 gene and any number of SMN2 copies) 2. Receiving a stable dosing regimen of 12 or 28 mg nusinersen for at least 6 months Exclusion Criteria: 1. An injury or surgery within the previous 3 months that would…
Contacts

Rafael Rodriguez-Torres, DPT

3472877093

rsr2157@cumc.columbia.edu

CONTACT

Cara Kanner, DPT

516-581-8150

chy2112@cumc.columbia.edu

CONTACT